CG Oncology, Inc. Cash Flow Statement
CGON / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
CG Oncology, Inc. used $132M in operating cash flow and negative free cash flow of $132M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$161.0M | -$88.0M | -$48.6M |
| Depreciation & Amortization | $1.4M | $32.0K | $17.0K |
| Operating Cash Flow | -$132.3M | -$78.7M | -$45.7M |
| Capital Expenditures | $134.0K | $234.0K | - |
| Free Cash Flow | -$132.5M | -$78.9M | - |